drugset / Trial / NCT00621023
Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This will be an open-label, non-randomized trial pilot phase II trial open to patients with myelodysplastic syndrome. The purpose of the study is to find out if the combination of decitabine, arsenic trioxide and ascorbic acid is safe.
Timeline
- Start
- 2007-11
- Primary completion
- 2010-04
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Vitamin C | Other / unclassified | 1000 mg | Intravenous |
| Subject | arsenic trioxide | Small molecule | 0.25 mg/kg | Intravenous |